MENU

Papers

2014

• Endo Y, Yamashita H, Takahashi S, Sato S, Yoshimoto N, Asano T, Hato Y, Dong Y, Fujii Y, Toyama T. Immunohistochemical determination of arylamine N-acetyltransferase 1 (NAT1) as the target of miR-1290 and prognostic biomarker of breast cancer. BMC Cancer. 2014 accepted
• Akechi T, Uchida M, Nakaguchi T, Okuyama T, Sakamoto N, Toyama T, Yamashita H. Difference of patient's perceived need in breast cancer patients after diagnosis. Jpn J Clin Oncol. 2014 Oct 16. pii: hyu165. [Epub ahead of print]
• Urano M, Shiraki N, Hara M, Toyama T, Shibamoto Y. Multi-detector row CT-guided marking technique for breast-conserving therapy of early breast cancer: margin positivity and local control rates. Breast Cancer. 2014 Sep 3. [Epub ahead of print]
• Mukai H, Aihara T, Yamamoto Y, Takahashi M, Toyama T, Sagara Y, Yamaguchi H, Akabane H, Tsurutani J, Hara F, Fujisawa T, Yamamoto N, Ohsumi S. The Japanese Breast Cancer Society Clinical Practice Guideline for systemic treatment of breast cancer. Breast Cancer.2014 Sep 9. [Epub ahead of print]
• Huang B, Omoto Y, Iwase H, Yamashita H, Toyama T, Coombes RC, Filipovic A, Warner M. Gustafsson JA. Differential expression of estrogen receptor α, β1, and β2 in lobular and ductal breast cancer. Proc Natl Acad Sci USA. 111(5):1933-8, 2014.
• Kawakubo T, Yasukochi A, Toyama T, Takahashi S, Okamoto K, Tsukuba T, Nakamura S, Ozaki Y, Nishigaki K, Yamashita H, Yamamoto K. Repression of cathepsin E expression increases the risk of mammary carcinogenesis and links to poor prognosis in breast cancer.Carcinogenesis. 35(3):714–726, 2014.
• Sato Y, Kondo M, Inagaki A, Komatsu H, Okada C, Naruse K, Sahashi T, Kuroda J, Ogura H, Uegaki S, Yoshida T, Mori Y, Sawada H, Watanabe S, Sugiura H, Endo Y, Yoshimoto N, Toyama T, Iida S, Yamada K, Kimura K, Wakita A. Highly Frequent and Enhanced Injection Site Reaction Induced by Peripheral Venous Injection of Fosaprepitant in Anthracycline-Treated Patients. Journal of Cancer. 5(5):390-397, 2014.
• Endo Y, Dong Y, Yoshimoto N, Asano T, Hato Y, Yamashita H, Sato S, Takahashi S, Fujii Y, Toyama T. HER2 Mutation Status in Japanese HER2-negative Breast Cancer Patients. Jpn J Clin Oncol. 44(7):619-23. 2014.
• Asano T, Sato S, Yoshimoto N, Endo Y, Hato Y, Dong Yu, Takahashi S, Fujii Y, Toyama T. High expression of LMTK3 is an independent factor indicating a poor prognosis in estrogen receptor α-positive breast cancer patients. Jpn J Clin Oncol. 2014. [Epub ahead of print]

2013

• Endo Y, Toyama T, Takahashi S, Yoshimoto N, Iwasa M, Asano T, Fujii Y, Yamashita H. MiR-1290 and its potential targets are associated with characteristics of estrogen receptor α-positive breast cancer. Endocr Relat Cancer. 20(1):91-102, 2013.
• Endo Y, Sugiura H, Yamashita H,Takahashi S,Yoshimoto N, Iwasa M, Asano, Toyama T. Myoepithelial Carcinoma of the Breast Treated with Surgery and Chemotherapy. Case Rep Oncol Med. 164761, 2013.
• Yamamoto Y, Ishikawa T, Hozumi Y, Ikeda M, Iwata H, Yamashita H, Toyama T, Chishima T, Saji S, Yamamoto-Ibusuki M, Iwase H. Randomized controlled trial of toremifene 120 mg compared with exemestane 25 mg after prior treatment with a non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancer. BMC Cancer. 13(1):239, 2013.
• Kawase M, Toyama T, Takahashi S, Sato S, Yoshimoto N, Endo Y, Asano T, Kobayashi S, Fujii Y, Yamashita H. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer. Breast Cancer. 2013 Jun 16. [Epub ahead of print]
• Tsutsui H, Mochizuki T, Inoue K, Toyama T, Yoshimoto N, Endo Y, Todoroki K, Min JZ, Toyo'oka T. High-Throughput LC-MS/MS Based Simultaneous Determination of Polyamines Including N-Acetylated Forms in Human Saliva and the Diagnostic Approach to Breast Cancer Patients. Anal Chem. 85(24):11835-42, 2013.
• Snyder CF, Blackford AL, Okuyama T, Akechi T, Yamashita H, Toyama T, Carducci MA, Wu AW. Using the EORTC-QLQ-C30 in clinical practice for patient management: identifying scores requiring a clinician's attention. Qual Life Res. 22(10):2685-91, 2013.

2012

• Toyama T, Kondo N, Endo Y, Sugiura H, Yoshimoto N, Iwasa M, Takahashi S, Fujii Y, Yamashita H. High expression of microRNA-210 is an independent factor indicating a poor prognosis in Japanese triple-negative breast cancer patients. Jpn J Clin Oncol. 42(4):256-63, 2012.
• Kobayashi S, Sugiura H, Ando Y, Shiraki N, Yanagi T, Yamashita H, Toyama T. Reproductive history and breast cancer risk. Breast Cancer. 19(4):302-8, 2012.
• Akechi T, Okuyama T, Uchida M, Nakaguchi T, Ito Y, Yamashita H, Toyama T, Komatsu H, Kizawa Y, Wada M. Perceived needs, psychological distress and quality of life of elderly cancer patients. Jpn J Clin Oncol. 42(8):704-10, 2012.

2011

• Okuyama T, Akechi T, Yamashita H, Toyama T, Nakaguchi T, Uchida M, Furukawa TA. Oncologists' recognition of supportive care needs and symptoms of their patients in a breast cancer outpatient consultation. Jpn J Clin Oncol. 41(11):1251-8, 2011.
• Yoshimoto N, Toyama T, Takahashi S, Sugiura H, Endo Y, Iwasa M, Fujii Y, Yamashita H. Distinct expressions of microRNAs that directly target estrogen receptor α in human breast cancer. Breast Cancer Res Treat. 130(1):331-9, 2011
• Yoshimoto N, Nishiyama T, Toyama T, Takahashi S, Shiraki N, Sugiura H, Endo Y, Iwasa M, Fujii Y, Yamashita H. Genetic and environmental predictors, endogenous hormones and growth factors and risk of estrogen receptor-positive breast cancer in Japanese women.Cancer Sci. 102(11):2065-72, 2011.
• Endo Y, Toyama T, Takahashi S, Sugiura H, Yoshimoto N, Iwasa M, Kobayashi S, Fujii Y, Yamashita H. High estrogen receptor expression and low Ki67 expression are associated with improved time to progression during first-line endocrine therapy with aromatase inhibitors in breast cancer. Int J Clin Oncol. 16(5):512-8, 2011.
• Yamashita H, Toyama T, Sugiura H, Yoshimoto N, Endo Y, Iwasa M, Fujii Y, Kobayashi S. Management of recurrent breast cancer without systemic therapy but with natural menopause as endocrine therapy: a report of two cases. The Open Breast Cancer Journal 3:10-12, 2011.
• Uchida M, Akechi T, Okuyama T, Sagawa R, Nakaguchi T, Endo C, Yamashita H, Toyama T, Furukawa TA. Patients' supportive care needs and psychological distress in advanced breast cancer patients in Japan. Jpn J Clin Oncol. 41(4):530-6, 2011.
• Akechi T, Okuyama T, Endo C, Sagawa R, Uchida M, Nakaguchi T, Akazawa T, Yamashita H, Toyama T, Furukawa TA. Patient's perceived need and psychological distress and/or quality of life in ambulatory breast cancer patients in Japan. Psychooncology. 20(5):497-505, 2011.
• Uchida M, Akechi T, Okuyama T, Sagawa R, Nakaguchi T, Endo C, Yamashita H, Toyama T, Furukawa TA. Patients' Supportive Care Needs and Psychological Distress in Advanced Breast Cancer Patients in Japan. Jpn J Clin Oncol. 41(4):530-6, 2011.
• Yamashita H, Iwase H, Toyama T, Takahashi S, Sugiura H, Yoshimoto N, Endo Y, Fujii Y, Kobayashi S. Estrogen receptor-positive breast cancer in Japanese women: trends in incidence, characteristics, and prognosis. Ann Oncol 22(6):1318-25, 2011.

2010

• Yoshimoto N, Yamashita T, Fujita T, Hayashi H, Tsunoda N, Kimura M, Tsuzuki N, Yamashita H, Toyama T, Kondo N, Iwata H.　Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer.Breast Cancer. 17(4):298-302, 2010.
• Sawaki M, Iwata H, Sato Y, Wada M, Toyama T, Sasaki E, Yatabe Y, Imai T, Ohashi Y. Phase II study of preoperative systemic treatment with the combination of docetaxel and trastuzumab in patients with locally advanced HER-2-overexpressing breast cancer. Breast. 19(5):370-6, 2010.

2009

• Toyama T, Yamashita H, Sugiura H, Kondo N, Iwase H, Fujii Y. No Association Between CYP2D6*10 Genotype and Survival of Node-negative Japanese Breast Cancer Patients Receiving Adjuvant Tamoxifen Treatment. Jpn J Clin Oncol. 39(10):651-6, 2009.
• Yoshimoto N, Yamashita T, Fujita T, Hayashi H, Tsunoda N, Kimura M, Tsuzuki N, Yamashita H, Toyama T, Kondo N, Iwata H. Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer.Breast Cancer. 17(4):298-302, 2009.
• Yamashita H, Takahashi S, Ito Y, Yamashita T, Ando Y, Toyama T, Sugiura H, Yoshimoto N, Kobayashi S, Fujii Y, Iwase H. Predictors of response to exemestane as primary endocrine therapy in estrogen receptor–positive breast cancer, Cancer Sci. 100(11):2028-33, 2009.
• Zhang ZH, Yamashita H, Toyama T, Yamamoto Y, Kawasoe T, Ibusuki M, Tomita S, Sugiura H, Kobayashi S, Fujii Y, Iwase H. Nuclear corepressor 1 expression predicts response to first-line endocrine therapy for breast cancer patients on relapse.Chin Med J 122(15):1764-1768. 2009.
• Okuyama T, Akechi T, Yamashita H, Toyama T, Endo C, Sagawa R, Uchida M, Furukawa TA. Reliability and validity of the Japanese version of the Short-form Supportive Care Needs Survey Questionnaire (SCNS-SF34-J). Psychooncology 18(9):1003-10, 2009.

2008

• Kondo N, Toyama T, Sugiura H, Fujii Y, Yamashita H:
  miR-206 expression is down-regulated in estrogen receptor α-positive human breast cancer.Cancer Res 68: 5004-5008, 2008
• Yamashita H, Nishio M, Toyama T, Sugiura H, Kondo N, Kobayashi S, Fujii Y, Iwase H:
  Low phosphorylation of ERα serine 118 and high phosphorylation of ERα serine 167 improve survival in ER-positive breast cancer. Endocr-Relat Cancer 15: 755-763, 2008
• Toyama T, Yamashita H, Kondo N, Okuda K, Takahashi S, Sasaki H, Sugiura H, Iwase H, Fujii Y:
  Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers.
  BMC Cancer 8: 309, 2008
• Hamaguchi M, Nishio M, Toyama T, Sugiura H, Kondo N, Fujii Y, Yamashita H:
  Possible difference in frequencies of genetic polymorphisms of estrogen receptor α, estrogen metabolism and p53 genes between estrogen receptor-positive and -negative breast cancers.
  Jpn J Clin Oncol 38: 734-742, 2008
• Kai K, Zhang Z, Yamashita H, Yamamoto Y, Miura Y, Iwase H:
  Loss of heterozygosity at the ATBF1-A locus located in the 16q22 minimal region in breast cancer.
  BMC Cancer 8: 262, 2008
• Okumura Y, Yamamoto Y, Zhang Z, Toyama T, Kawasoe T, Ibusuki M, Honda Y, Iyama K, Yamashita H, Iwase H:
  Identification of biomarkers in ductal carcinoma in situ of the breast with microinvasion.
  BMC Cancer 8: 287, 2008
• Yamashita H:
  Current research topics in endocrine therapy for breast cancer.
  Int J Clin Oncol 13: 380-383, 2008 (review)
• Kobayashi S:
  Basal-like subtype of breast cancer: a review of its unique characteristics and clinical significance.
  Breast Cancer 15: 153-158, 2008 (review)

2007

• Toyama T, Zhang Z, Nishio M, Hamaguchi M, Kondo N, Iwase H, Iwata H, Takahashi S, Yamashita H, Fujii Y:
  Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients.
  Breast Cancer Res 9: R34, 2007
• Sugiura H, Toyama T, Hara Y, Zhang Z, Kobayashi S, Fujii Y, Iwase H, Yamashita H:
  Expression of estrogen receptor β wild-type and its variant ERβcx/β2 is correlated with better prognosis in breast cancer.
  Jpn J Clin Oncol 37: 820-828, 2007
• Mita K, Zhang Z, Ando Y, Toyama T, Hamaguchi M, Kobayashi S, Hayashi S, Fujii Y, Iwase H, Yamashita H:
  Prognostic significance of insulin-like growth factor binding protein (IGFBP)-4 and IGFBP-5 expression in breast cancer.
  Jpn J Clin Oncol 37: 575-582, 2007
• Naiki-Ito A, Asamoto M, Hokaiwado N, Takahashi S, Yamashita H, Tsuda H, Ogawa K, Shirai T:
  Gpx2 is an overexpressed gene in rat breast cancers induced by three different chemical carcinogens.
  Cancer Res 67: 11353-11358, 2007
• Arihiro K, Umemura S, Kurosumi M, Moriya T, Oyama T, Yamashita H, Umekita Y, Komoike Y, Shimizu C, Fukushima H, Kajiwara H, Akiyama F:
  Comparison of evaluations for hormone receptors in breast carcinoma using two manual and three automated immunohistochemical assays.
  Am J Clin Pathol 127: 356-365, 2007
• Fujinaka Y, Takane K, Yamashita H, Vasavada RC:
  Lactogens promote beta cell survival through JAK2/STAT5 activation and BCL-XL upregulation.
  J Biol Chem 282: 30707-30717, 2007

2006

• Zhang Z, Yamashita H, Toyama T, Yamamoto Y, Kawasoe T, and Iwase H:
  Reduced expression of the breast cancer metastasis suppressor 1 mRNA is correlated with poor progress in breast cancer.
  Clin Cancer Res 12: 6410-6414, 2006
• Yamashita H, Nishio M, Ando Y, Zhang Z, Hamaguchi M, Mita K, Kobayashi S, Fujii Y, Iwase H:
  Stat5 expression predicts response to endocrine therapy and improves survival in estrogen receptor-positive breast cancer.
  Endocr-Relat Cancer 13: 885-893, 2006
• Yamashita H, Toyama T, Nishio M, Ando Y, Hamaguchi M, Zhang Z, Kobayashi S, Fujii Y, Iwase H:
  p53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer.
  Breast Cancer Res 8: R48, 2006
• Zhang Z, Yamashita H, Toyama T, Sugiura H, Ando Y, Mita K, Hamaguchi M, Hara Y, Kobayashi S, Iwase H:
  NCOR1 mRNA is an independent prognostic factor for breast cancer.
  Cancer Lett 237: 123-129, 2006
• Toyama T, Zhang Z, Iwase H, Yamashita H, Ando Y, Hamaguchi M, Mizutani M, Kondo N, Fujita T, Fujii Y, Iwata H:
  Low expression of the Snail gene is a good prognostic factor in node-negative invasive ductal carcinomas.
  Jpn J Clin Oncol 36: 357-363, 2006
• Yamashita H, Ando Y, Nishio M, Zhang Z, Hamaguchi M, Mita K, Kobayashi S, Fujii Y, Iwase H:
  Immunohistochemical evaluation of hormone receptor status for predicting response to endocrine therapy in metastatic breast cancer.
  Breast Cancer 13: 74-83, 2006
• Umemura S, Kurosumi M, Moriya T, Oyama T, Arihiro K, Yamashita H, Umekita Y, Komoike Y, Shimizu C, Fukushima H, Kajiwara H, Akiyama F:
  Immunohistochemical evaluation for hormone receptors in breast cancer: A practically useful evaluation system and handling protocol.
  Breast Cancer 13: 232-235, 2006
• Yamashita T, Yamashita H, Itoh Y, Karamatsu S, Itoh K, Hara Y, Ando Y, Sugiura H, Kuzushima T, Toyama T, Iwata H, Kobayashi S, Iwase H:
  Clinical usefulness of oral combination chemotherapy of 5'-deoxy-5-fluorouridine (5-DFUR) and cyclophosphamide for metastatic breast cancer.
  Breast Cancer 13: 334-339, 2006

2005

• Zhang Z, Yamashita H, Toyama T, Sugiura H, Ando Y, Mita K, Hamaguchi M, Kawaguchi M, Miura Y, Iwase H:
  ATBF1-A messenger RNA expression is correlated with better prognosis in breast cancer.
  Clin Cancer Res 11: 193-198, 2005
• Yamashita H, Nishio M, Kobayashi S, Ando Y, Sugiura H, Zhang Z, Hamaguchi M, Mita K, Fujii Y, Iwase H:
  Phosphorylation of estrogen receptor α serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer.
  Breast Cancer Res 7: R753-R764, 2005
• Zhang Z, Yamashita H, Toyama T, Sugiura H, Ando Y, Mita K, Hamaguchi M, Hara Y, Kobayashi S, Iwase H:
  Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast.
  Breast cancer Res Treat 94: 11-16, 2005

2004

• Zhang Z, Yamashita H, Toyama T, Sugiura H, Omoto Y, Ando Y, Mita K, Hamaguchi M, Hayashi S-I, Iwase H:
  HDAC6 expression is correlated with better prognosis in breast cancer.
  Clin Cancer Res 10: 6962-6968, 2004
• Yamashita H, Nishio M, Toyama T, Sugiura H, Zhang Z, Kobayashi S, Iwase H:
  Coexistence of HER2 overexpression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer.
  Breast Cancer Res 6: R24-R30, 2004
• Yamashita H, Nishio M, Fujii Y, Iwase H:
  Dominant-negative Stat5 inhibits growth and induces apoptosis in T47D-derived tumors in nude mice.
  Cancer Sci 95: 662-665, 2004
• Nishimura R, Tominaga T, Mitsuyama S, Aoyama H, Asaga T, Ohno S, Okuyama N, Kimura M, Iwase H, Kanda K, Koga T, Shiba E, Ikeda T:
  Combination chemotherapy with docetaxel and doxifluridine showed a beneficial outcome in advanced or recurrent breast cancer patients with longer disease-free interval.
  Anticancer Res 24: 2085-91, 2004
• Toyama T, Iwase H:
  p33ING1b and estrogen receptor (ER) alpha.
  Breast Cancer 11: 33-37, 2004 (review)
• Kobayashi S:
  What caused the decline in breast cancer mortality in the United Kingdom?
  Breast Cancer, 11: 156-159, 2004 (review)

2003

• Yamashita H, Iwase H, Toyama T, Fujii Y:
  Naturally occurring dominant-negative Stat5 suppresses transcriptional activity of estrogen receptors and induces apoptosis in T47D breast cancer cells.
  Oncogene 22: 1638-1652, 2003
• Toyama T, Iwase H, Yamashita H, Hara Y, Sugiura H, Zhang Z, Fukai I, Miura Y, Riabowol K, Fujii Y:
  p33ING1b stimulates the transcriptional activity of the estrogen receptor α via its activation function (AF) 2 domain.
  J Steroid Biochem Mol Biol 87: 57-63, 2003
• Iwase H, Omoto Y, Toyama T, Yamashita Y, Hara Y, Sugiura H, Zhang Z:
  Clinical significance of AIB1 expression in breast cancer.
  Breast Cancer Res Treat 80: 339-345, 2003
• Zhang Z, Yamashita H, Toyama T, Omoto Y, Sugiura H, Hara Y, Wu X, Kobayashi S, Iwase H:
  Quantitative determination by real-time RT-PCR of aromatase mRNA in invasive ductal carcinoma of the breast.
  Breast Cancer Res 5: R250-R256, 2003
• Toyama T, Iwase H, Yamashita H, Hara Y, Omoto Y, Sugiura H, Zhang Z, Fujii Y:
  Reduced expression of the Syk gene is correlated with poor prognosis in human breast cancer.
  Cancer Lett 189: 97-102, 2003
• Zhang Z, Yamashita H, Toyama T, Omoto Y, Sugiura H, Hara Y, Haruki N, Kobayashi S, Iwase H:
  Estrogen receptor alpha mutation (A-to-G transition at mucleotide 908) is not found in different types of breast lesions from Japanese women.
  Breast Cancer 10: 70-73, 2003
• Toyama T, Yamashita H, Hara Y, Sugiura H, Fujii Y, Iwase H:
  Biweekly paclitaxel in patients with metastatic breast cancer.
  Int J Clin Oncol 8: 357-361, 2003
• Iwase H, Zhang Z, Omoto Y, Sugiura H, Yamashita H, Toyama T, Iwata H, Kobayashi S:
  Clinical significance of the expression of estrogen receptors alpha and beta for endocrine therapy of breast cancer.
  Cancer Chemother Pharmacol 52: 34-38, 2003 (review)
• Iwase H:
  Molecular action of the estrogen receptor and hormone dependency in breast cancer.
  Breast Cancer 10: 89-96, 2003 (review)

2002

• Zhang Z, Yamashita H, Toyama T, Omoto Y, Hara Y, Sugiura H, Kobayashi S, Harada N, Iwase H:
  Semi-quantitative immunohistochemical analysis of aromatase expression in ductal carcinoma in situ of the breast.
  Breast Cancer Res Treat 74: 47-53, 2002
• Omoto Y, Kobayashi S, Inoue S, Ogawa S, Toyama T, Yamashita H, Muramatsu M, Gustafsson JA, Iwase H:
  Evaluation of oestrogen receptor β wild-type and variant protein expression, and relationship with clinicopathological factors in breast cancers.
  Eur J Cancer 38: 380-386, 2002
• Yamashita H, Iwase H:
  The role of Stat5 in estrogen receptor-positive breast cancer.
  Breast Cancer 9: 312-318, 2002 (review)
• Vieyra D, Toyama T, Hara Y, Boland D, Johnston R, Riabowol K:
  ING1 isoforms differentially affect apoptosis in a cell age-dependent manner.
  Cancer Res 62: 4445-4452, 2002
• Moriyama S, Nakashima Y, Yano M, Kaji M, Yamakawa Y, Toyama T, Yamashita H, Iwase H, Sasaki H, Saito Y, Kiriyama M, Kato J, Fujii Y:
  Ratio of expression of p16(INK4a) to p14(ARF) correlates with the progression of non-small cell lung cancer.
  Jpn J Cancer Res 93: 783-788, 2002
• Mitsui A, Kuwabara Y, Iwase H, Mitani M, Shinoda N, Sato A, Toyama T, Sugiura M, Suzuki T, Kato J, Fujii Y:
  Telomerase activity in esophageal squamous cell carcinoma: Down-regulation by chemotherapeutic agent.
  J Surg Oncol 79: 37-45, 2002

2001

• Iwase H, Ando Y, Ichihara S, Toyoshima S, Nakamura T, Karamatsu S, Ito Y, Toyama T, Yamashita Y, Omoto Y, Mitsuyama S, Kobayashi S:
  Immunohistochemical analysis on biological markers in ductal carcinoma in situ of the breast.
  Breast Cancer 8: 98-104, 2001
• Iwata H, Yamamoto M, Nemori R, Mizutani M, Iwase T, Miura S, Obata Y, Hara Y, Omoto Y, Toyama T, Yamashita H, Iwase H, Kobayashi S:
  Localization of gelatinolytic activity can be detected in breast cancer tissues by film in situ zymography.
  Breast Cancer 8: 111-5, 2001
• Omoto Y, Inoue S, Iwase H, Yamashita H, Toyama T, Hara Y, Ogawa S, Muramatsu M, Kobayashi S:
  Clinical value of the wild-type estrogen receptor beta expression in breast cancer.
  Cancer Lett 163: 207-212, 2001
• Hara Y, Iwase H, Toyama T, Yamashita H, Omoto Y, Fujii Y, Kobayashi S:
  Telomerase activity levels are useful in evaluating the surgical margin in breast conserving surgery for breast cancer.
  Surg Today 31: 289-94, 2001
• Naito A, Iwase H, Kuzushima T, Nakamura T, Kobayashi S:
  Clinical significance of E-cadherin expression in thyroid neoplasms.
  J Surg Oncol 76: 176-80, 2001
• Toyama T, Yamashita H, Hara Y, Hikosaka Y, Kobayashi S, Iwase H:
  Successful management of breast cancer with liver metastases with medroxyprogesterone acetate treatment.
  Int J Clin Oncol 6: 306-309, 2001
• Ito Y, Iwase H, Tanaka H, Yuasa H, Kureyama Y, Yamashita H, Toyama T, Kimura M, Kobayashi S:
  Metachronous primary hyperparathyroidism due to a parathyroid adenoma and a subsequent carcinoma report of a case.
  Surgery Today 31: 895-898, 2001
• Omoto Y, Kobayashi Y, Nishida K, Tsuchiya E, Eguchi H, Nakagawa K, IshikawaY, Yamori T, Iwase H, Fujii Y, Warner M, Gustafsson Jk, Hayashi S-I:
  Expression, function, and clinical implications of the estrogen receptor beta in human lung cancers.
  Biochem Biophys Res Commun 285: 340-347, 2001
• Park S-H, Yamashita H, Rui H, Waxman DJ:
  Serine phosphorylation of growth hormone-activated STAT5a and STAT5b: Impact on STAT5 transcriptional activity.
  Mol Endocrinol 15: 2157-2171, 2001

2000

• Ando Y, Iwase H, Ichihara S, Toyoshima S, Nakamura T, Yamashita H, Toyama T, Omoto Y, Karamatsu S, Mitsuyama S, Fujii Y, Kobayashi S:
  Loss of heterozygosity and microsatellite instability in ductal carcinoma in situ of the breast.
  Cancer Lett 156: 207-214, 2000
• Itoh Y, Tanaka H, Iwase H, Karamatsu S, Yamashita H, Itoh K, Yamashita T, Toyama T, Omoto Y, Kobayahsi S:
  Readministration of tamoxifen after adjuvant therapy for recurrent breast cancer.
  Breast Cancer 7: 149-152, 2000
• Kobayashi S, Ito Y, Ando Y, Omoto Y, Toyama T, Iwase H:
  Comparison of Five Different antibodies in the immunohistochemical assay of estrogen receptor alpha in human breast cancer.
  Breast Cancer 7: 136-141, 2000
• Omoto Y, Iwase H, Iwata H, Hara Y, Ando Y, Kobayashi S:
  Expression of estrogen receptor alpha exon 5 and 7 deletion variant in human breast cancer.
  Breast Cancer 7: 27-31, 2000
• Moriya T, Kasami M, Akiyama F, Ichihara S, Kurosumi M, Tsuda H, Umemura S, Akashi-Tanaka S, Imamura H, Iwase H, Shin E, Harada Y, Mitsuyama S, Ohuchi N:
  A proposal for histopathological diagnosis of ductal carcinoma in situ of the breast.
  Breast Cancer 7: 321-325, 2000
• Koyama H, Iwata H, Kuwabara Y, Iwase H, Kobayashi S and Fujii Y:
  Gelatinolytic activity of matrix metalloproteinase-2 and -9 in oesophageal carcinoma; a study using in situ zymography.
  Eur J Cancer 36: 2164-2170, 2000
• Nomura Y, Masaoka A, Fujii Y, Kobayashi S, Iwase H, Iwata H. et al:
  Clinical dosage determination of a new aromatase inhibitor, anastrozole, in postmenopausal Japanese women with advanced breast cancer.
  Clin Drug Invest 20: 357-369, 2000
• Kurebayashi J, Sonoo H, Inaji H, Nishimura R, Iino Y, Toi M, Kobayashi S, Saeki T:
  Endocrine therapies for patients with recurrent breast cancer: predictive factors for responses to first- and second-line endocrine therapies.
  Oncology 59 (suppl 1): 31-37, 2000
• Nevalainen MT, Ahonen T, Yamashita H, Chandrashekar V, Bartke A, Grimley PM, Robinson GW, Hennighausen L, Rui H:
  Epithelial defect in prostates of Stat5a null mice.
  Lab Invest 80: 993-1006, 2000

1999

• Iwase H, Iwata H, Omoto Y, Toyama T, Hara Y, Ando Y, Ito Y, Fujii Y, Kobayashi S:
  DNA methylation analysis at diatal and proximal promotor regions of the oestrogen receptor gene in breast cancers.
  Br J Cancer 80: 1982-1986, 1999
• Iwase H, Omoto Y, Toyama T, Hara Y, Kobayahsi S:
  Clinical significance of estrogen receptor beta in breast cancer.
  Breast Cancer 6: 325-330, 1999
• Kobayashi S, Iwase H, Kuzushima K, Iwata H, Toyama T, Hara Y, Omoto Y, Ando Y, and Nakamura T:
  Consecutively occuring multiple fibroadenomas of the breast distingushed from phyllodes tumors by clonality analysis of stromal tissues.
  Breast Cancer 6: 201-206, 1999
• Omoto Y, Iwase H, Iwata H, Hara Y, Ando Y, Kobayashi S:
  Upper airway obstruction due to benign goiter: Report of three cases.
  Thyroidol Clin Exp 11: 57-59, 1999
• Toyama T, Iwase H, Garkavtsev I, Watson P, Muzik H, Saettler E, Magliocco A, DiFrancesco L, Forsyth P, Kobayashi S, Riabowol K:
  Suppression of ING1 expression in sporadic breast cancer.
  Oncogene 18: 5187-5193, 1999
• Yamashita H, Xu J, Erwin RA, Larner AC, Rui H:
  A lymphoma growth inhibitior blocks some but not all prolactin-stimulated signaling pathways.
  J Biol Chem 274: 14699-14705, 1999
• Ohmori M, Nagai M, Tasaka T, Koeffler HP, Toyama T, Riabowol K, Takahara J:
  Decreased expression of p33ING1 mRNA in lymphoid malignancies.
  Am J Hematol 62: 118-9, 1999

1998

• Kobayashi S, Iwase H, Kawarada Y, Miura N, Sugiyama T, Iwata H, Hara Y, Omoto Y, Nakamura T:
  Detection of DNA fragmentation in human breast cancer tissue by an antibody specific to single-stranded DNA.
  Breast Cancer 5: 47-52, 1998
• Iwase H, Omoto Y, Iwata H, Hara Y, Ando Y, Kobayashi S:
  Genetic and epigenetic alteration of the estrogen receptor gene and hormone independence in human breast cancer.
  Oncology 55 (Suppl 1):11-6, 1998 (review)
• Kobayashi S, Tajima T:
  Current insights in the mechanisms of carcinogenesis, progress, and metastasis of breast cancer.
  Breast Cancer 5: 340-343, 1998 (review)
• Kobayashi S, Fujimori M, Shingu K, Ito K, Hama K, Amano J:
  Clinical micro carcinoma of the thyroid gland.
  Thyroid Clin Exp 10: 175-176, 1998
• Kobayashi S, Iwase H, Toyama T, Hara Y, Omoto Y, Nakamura T:
  Absence of microsatellite instability in thyroid tumors from Japanese patients.
  Thyroid Clin Exp 10: 1-6, 1998
• Wanibe M, Mizuno H, Watanabe M, Matsuba K, Iwase H, Kobayashi S:
  Effectiveness of thyroid hormone rectal suppositories in thyroidectomized patients.
  J Applied Therapeutic Res 2: 133-140, 1998
• Yamashita H, Xu J, Erwin RA, Farrar WL, Kirken RA, Rui H:
  Differential control of the phosphorylation state of proline-juxtaposed serine residues Ser725 of Stat5a and Ser730 of Stat5b in prolactin-sensitive cells.
  J Biol Chem 273: 30218-30224, 1998
• Parr E, Toyama T, Hull C, Meyyappan M, Bestilny L, Wheaton K, Riabowol K:
  Molecular aspects of cellular senescence in human diploid fibloblasts.
  Current Science, 74: 878-883, 1998

1997

• Kobayashi S, Iwase H, Ito Y, Yamashita H, Iwata H, Yamashita T, Ito K, Toyama T, Nakamura T, Masaoka A:
  Clinical significance of bcl-2 gene expression in human breast cancer tissues.
  Breast Cancer Res Treat 42: 173-181, 1997
• Iwase H, Itoh Y, Kuzushima T, Yamashita H, Iwata H, Toyama T, Hara Y, Masaoka A:
  Simultaneous quantitative analysis of c-erbB-2 protein, epidermal growth factor receptor, cathepsin D, and hormone receptors in breast cancer.
  Cancer Detect Prevent 21: 29-35, 1997
• Iwase H, Iwata H, Toyama T, Hara Y, Omoto Y, Ando Y, Nakamura T, Kobayashi S:
  The clinical value of microsatellite instability and a loss in heterozygosity in sporadic breast cancers.
  Breast Cancer 4: 234-238, 1997
• Iwase H, Kobayashi S:
  Alterations and polymorphisms of the estrogen receptor gene in breast cancer.
  Breast Cancer 4: 57-66, 1997 (review)

1996

• Toyama T, Iwase H, Yamashita H, Yamashita T, Ito K, Hara Y, Suchi M, Kato T, Nakamura T, Kobayashi S:
  Microsatellite instability in sporadic human breast cancer.
  Int J Cancer 68: 447-451, 1996
• Iwata H, Kobayashi S, Iwase H, Masaoka A, Fujimoto N, Okada Y:
  Production of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human breast carcinomas.
  Jpn J Cancer Res 87: 602-611, 1996
• Iwase H, Greenman JM, Barnes DM, Hodgson S, Bobrow L, Mathew CG:
  Sequence variants of the estrogen receptor (ER) gene found in breast cancer patients with ER negative and progesterone receptor positive tumors.
  Cancer Lett 108: 179-184, 1996
• Toyama T, Iwase H, Iwata H, Hara Y, Omoto Y, Suchi M, Kato T, Nakamura T, Kobayashi S:
  Microsatellite instability in in situ and invasive breast cancer of Japanese women.
  Cancer Lett 108: 205-209, 1996
• Yamashita T, Iwase H, Yamashita H, Iwata H, Ito K, Toyama T, Hara Y, Kobayashi S:
  Low frequent loss of heterozygosity in the BRCA 1 region in Japanese sporadic breast cancer.
  Breast Cancer 3: 167-172, 1996
• Iwata H, Kobayashi S, Iwase H, Itoh Y, Kuzushima T, Naitoh A, Yamashita T, Itoh K, Toyama T, Masaoka A:
  Flow cytometric assay of c-erbB-2 protein in fine needle aspirates of fresh and frozen human breast cancer tissues.
  Breast Cancer 3: 111-117, 1996

1995

• Iwase H, Greenman JM, Baenes DM, Bobrow L, Hodgson S, Mathew CG:
  Loss of heterozygosity of the oestrogen receptor gene in breast cancer.
  Br J Cancer 71: 448-450, 1995
• Itoh Y, Kobayashi S, Iwase H, Yamashita H, Kuzushima T, Iwata H, Yamashita T, Naito A, Itoh K, Masaoka A:
  Clinical significance of cathepsin D assay in breast cancer tissues.
  J Surg Oncol 60: 221-226, 1995

1994

• Iwase H, Kobayashi S, Itoh Y, Fukuoka H, Kuzushima T, Iwata H, Yamashita T, Naitoh A, Itoh K, Masaoka A:
  Evaluation of serum tumor markers in patients with advanced or recurrent breast cancer.
  Breast Cancer Res Treat 33: 83-88, 1994
• Yamashita H, Kobayashi S, Iwase H, Itoh Y, Masaoka A:
  Recurrent breast cancer at 21 years after resection detected by serum tumor markers and manifested as dermatomyositis.
  Breast Cancer, 1: 65-68, 1994
• Tateyama H, Yang Y, Eimoto T, Tada T, Inagaki H, Nakamura T, Iwase H, Kobayashi S:
  Proliferating cell nuclear antigen expression in follicular tumors of the thyroid with special reference to oxyphilic cell lesions.
  Virchows Archiv 424: 533 537, 1994

1993

• Iwase H, Kobayashi S, Itoh Y, Kuzushima T, Yamashita H, Iwata H, Yamashita T, Naito A, Itoh K, Masaoka A:
  Clinical value of enzyme immunoassay of epidermal growth factor receptor in human breast cancer.
  Breast Cancer Res Treat 28: 215-221, 1993
• Yamashita H, Kobayashi S, Iwase H, Itoh Y, Kuzushima T, Iwata H, Naito A, Yamashita T, Masaoka A, Kimura N:
  Analysis of oncogenes and tumor suppressor genes in human breast cancer.
  Jpn J Cancer Res 84: 871-878, 1993

-1992

• Kobayashi S, Iwase H, Ito Y, Fukuoka H, Yamashita H, Kuzushima T, Iwata H, Masaoka A, Kimura N:
  Estrogen receptor, c-erbB-2 and nm23/NDP kinase expression in the intraductal and invasive components of human breast cancer.
  Jpn J Cancer Res 83: 859-865, 1992
• Kobayashi S, Iwase H, Matsuo K, Fukuoka H, Ito Y, Masaoka A:
  Primary adrenocortical tumors in autopsy records -A survey of "Cumulative reports in Japan" from 1973 to 1984.
  Jpn J Surg 21: 494-498, 1991
• Tanaka H, Kobayashi S, Masaoka A, Honda S, Yamaguchi K:
  Hypercalcemia induced by parathyroid hormone-related protein from lung cancer tissue.
  Chest 100: 1451-1453, 1991
• Kobayashi S, Iwase H:
  Prognostic factors and evaluation of effect in drug therapy of breast cancer, Cancer Chemotherapy; Challenges for the future.
  Vol. 5, p.183 190, Excerpta Medica Ltd (Tokyo) 1990
• Kobayashi S, Iwase H, Karamatsu S, Matsuo K, Masaoka A, Miyagawa T:
  The clinical value of serum CA 15-3 assay postoperatively in breast cancer patients.
  Jpn J Surg 19: 278-282, 1989
• Kobayashi S, Tobioka N, Samoto T, Kobayashi M, Iwase H, Masaoka A, Nakamura T, Shibata H, Amoh H, Matsuyama M.:
  Breast cancer with osteoclast-like multinucleated giant cells.
  Acta Pathol Jpn 34:1475-84, 1984
• Nagai R, Kataoka M, Kobayashi S, Ishihara K, Tobioka N, Nakashima K, Nruse M, Sauto K, Sakuma S:
  Estrogen and progesterone receptors in human breast cancer with concomitant assay of plasma 17beta-estradiol, progesterone, and prolactin levels.
  Cancer Res 39: 1834-1840, 1979
• Nomura Y, Kobayashi S, Takatani O, Sugano H, Matsumoto K, McGuire WL:
  Estrogen receptor and endocrine responsiveness in Japanese versus American breast cancer patients.
  Cancer Res 37: 106-10, 1977
• Kobayashi S:
  Studies on the estrogen-receptors in human breast cancer.
  Nagoya Med J 16: 165-76, 1971

〒467-8602
名古屋市瑞穂区瑞穂町字川澄1番地
Tel:052-851-5511（代表）

•